Best Matias Serebrinsky Podcasts (2024)

1
Transcranial Focused Ultrasound for Mental Health with Jay Sanguinetti of Sanmai 59:47

11d ago59:47

59:47

Greg and Matias interview Jay Sanguinetti, founder of Sanmai Technologies, a startup using transcranial focused ultrasound for the treatment of mental health conditions. Jay has a background in academia, having worked at the University of Arizona and started the SEMA Lab (Science Enhanced Mindful Awareness). In this episode, we discuss: The science…

1
Marie-Christine Levet: Founding Partner at Educapital 47:02

16d ago47:02

47:02

Marie-Christine Levet is the President and co-founder of Educapital, the first and largest Edtech impact fund in Europe. Based in Paris, Educapital invests in innovative startups from late seed to Series B, focusing on entrepreneurs who are transforming the future of education and work. The fund manages two portfolios and recently closed its second…

1
Navigating FDA clinical trials in Neurotech with Tim Marjenin 41:02

21d ago41:02

41:02

Greg and Matias interview Tim Marjenin, a regulatory consultant at MCRA with 16 years of experience at the FDA, to discuss the regulatory landscape for neurotechnology devices. Tim provides insights into the FDA approval process for neurotech devices, drawing from his extensive experience on the FDA's Neurostimulation-Neurology Devices Team. The ep…

1
Nick Moran: Founder & General Partner of New Stack Ventures. 46:24

29d ago46:24

46:24

Nick Moran is the Founder and General Partner of New Stack Ventures. A former M&A and Product Management professional at Danaher, Nick began angel investing full-time in 2013. In 2014, he launched the first venture capital podcast, The Full Ratchet, growing it into one of the largest media brands in venture capital and the top 0.5% of most listened…

1
Environmental Toxins and Mental Health with Gurdane Bhutani 49:17

2M ago49:17

49:17

Greg and Matias interview Gurdane Bhutani, an investor at MBX Ventures, to discuss the impact of environmental toxins on health and the field of exposomics. Gurdane is an expert in environmental health, with a background in Epidemiology and Environmental Health Sciences. He provided insights into the pervasive nature of environmental toxins and the…

1
Charles Hudson: Managing Partner at Precursor Ventures 50:05

2M ago50:05

50:05

Charles Hudson is the Managing Partner and Founder of Precursor Ventures, an early stage venture capital firm focused on investing in the first institutional round of investment for the most promising software and hardware companies. Under his leadership, Precursor Ventures has raised four funds and has over $200 million under management. He has i…

1
Samara Mejia Hernandez: Founding Partner at Chingona Ventures 52:33

2M ago52:33

52:33

Samara is the Founding Partner of an institutionally backed pre-seed stage fund, Chingona Ventures, focusing on investing in tech and tech-enabled companies across the U.S. The fund has $60MM in AUM and has made over 40 investments across technology sectors in Financial, Food, Future of Work and Learning, and Health/Wellness. Before this, she was a…

1
Shawn Merani: Founder & Managing Director at Parade Ventures 48:08

3M ago48:08

48:08

Shawn Merani is the Founder and Managing Partner of Parade Ventures, a pre-seed & seed stage-focused venture capital firm. Previously, Shawn was a co-founder and partner at Flight Ventures, investing in early stage software, internet and mobile companies across a variety of sectors. Additionally, he has invested in select later stage companies. Sha…

1
FDA advisors say no to MDMA. What’s the impact? With Josh Hardman 56:55

3M ago56:55

56:55

Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD. Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting. In this episode, …

1
Ali Jamal: Founding Partner of First Check Ventures 50:48

3M ago50:48

50:48

Ali Jamal is a Venture Investor, Product Leader, Growth Expert, Data Scientist, and Corporate Strategist. He is the Founder of First Check Ventures, a venture capital firm that invests in early-stage startups worldwide. The syndicate has supported and invested in more than 130 startups from over 30 countries, including the US, Pakistan, India, Sing…

1
Matias Serebrinsky: Managing Partner at PsyMed Ventures 46:34

4M ago46:34

46:34

Matias is a General Partner at PsyMed Ventures, a venture capital fund that invests in cutting-edge brain and mental health technologies. Prior to this role, he led NVIDIA's accelerator program for AI startups in North America. Before his work at NVIDIA, Matias co-founded CookUnity, a venture-backed food technology company that has delivered over o…

1
Leck Ting Yan: Managing Partner at TRIVE 46:32

4M ago46:32

46:32

Ting Yan is the Managing Partner at TRIVE, an early-stage venture capital firm in Southeast Asia that focuses on investing in impactful, high-growth technology companies. Ting Yan dedicates the majority of his time to working closely with TRIVE's portfolio founders to help structure their businesses for growth. Prior to joining TRIVE, Ting Yan bega…

1
Investing in New Frontiers of Mental Health (Live at SXSW) 50:33

4M ago50:33

50:33

Software, hardware, and biotechnology are playing an increasingly transformative role in our mental health and wellness. Join us as we discuss what investors look for in these new companies and how they separate what’s real — and what’s near-term — from what’s hype. We’ll explore AI-powered tools for mental health, the new area of “enerceuticals” (…

1
Gabriel Jarrosson: Managing Partner at Lobster Capital 48:01

5M ago48:01

48:01

Gabriel Jarrosson is a seasoned investor and entrepreneur with over a decade of experience in the startup space and the General Partner of Lobster Capital. He has invested over $25M in Y Combinator startups. Having sold three of his own startups, he shares his expertise in his books "My Investor Secrets" and "Investing in Startups: x100 or Nothing.…

1
Comparing Psychedelic Compounds in Therapy (Live Panel at Battery SF) 1:01:53

5M ago1:01:53

1:01:53

Matias hosted a panel at The Battery SF with renowned psychedelics experts, Nolan Williams, Allison Feduccia, Matt Baggott. Nolan is a Stanford professor currently researching ibogaine among other areas in psychiatry and radiology, and he's a founder of TMS company Magnus Medical. Allison is the founder of Psychedelic Support, a platform providing …

1
What Payers Want with Lili Brillstein 48:20

6M ago48:20

48:20

Matias interviews Lili Brillstein about how to work collaboratively with healthcare payers (the ones that reimburse for medical expenses). Lili is a pioneer in the field, having previously led one of the largest bundled payment initiatives at Horizon Blue Cross Blue Shield. She currently is the founder of her own advisory firm, BCollaborative, wher…

1
Decoding the Brain with Ed Boyden 50:37

7M ago50:37

50:37

Greg and Matias interview Ed Boyden about neuroscience frontiers and its applications to mental health. Ed is a pioneer in understanding the fundamental mechanisms of the brain. He runs a lab at MIT for Synthetic Neurobiology and is a professor across the departments of neurotechnology, biological engineering, and cognitive science at MIT’s McGover…

1
5-MeO-DMT in mental healthcare with Steve Rio 50:25

8M ago50:25

50:25

Greg and Matias interview Steve Rio about 5-MeO-DMT and its potential role in mental healthcare. Steve is a social impact cofounder, transformational coach, and practitioner at the Enfold Institute, one of the most reputable aboveground retreat centers working with 5-MeO-DMT. He shared many insights from his hands-on experience guiding hundreds of …

1
Tom Insel: Startups, AI, Psychedelics, and SSRIs 57:50

9M ago57:50

57:50

Tom Insel is an entrepreneur and former director of the US National Institute of Mental Health, the lead US agency supporting mental health research with a $2 billion budget. Since his time at the NIMH, Tom has built mental health technology, first at Verily and Mindstrong Health, and more recently founded Vanna Health, an online healthcare provide…

1
Food as Medicine for Mental Health: Drew Ramsey 46:19

10M ago46:19

46:19

What if your next antidepressant was a clam or spinach? Greg & Matias invite Dr. Drew Ramsey to explore nutritional psychiatry - a field exploring how the food we eat can be as powerful as medication in treating mental illnesses like depression and anxiety. Dr. Drew Ramsey is a psychiatrist, entrepreneur and author focusing on nutritional intervent…

1
Ketogenic Diet for Brain Health: Jan Baszucki 44:19

10M ago44:19

44:19

Can diet treat mental illness? Greg and Matias interview Jan Baszucki of the Baszucki Group whose son Matt overcame bipolar through the ketogenic diet. Jan has supported studies on ketogenic diets and fasting protocols for conditions like depression, schizophrenia, and bipolar disorder. In this episode we discuss: The powerful personal story behind…

1
Investing in Neurotech 101: Alex Morgan of Khosla Ventures 54:38

11M ago54:38

54:38

Advancements in neuroscience, AI, and bioengineering are unlocking new possibilities for neurotechnologies. Investors are paying attention. Alex Morgan of Khosla Ventures is an MD, PhD, physicist, and one of the most active investors in neurotech startups. He's backed companies harnessing neuromodulation for varied applications - from sleep (Somnee…

1
All you need is d̶r̶u̶g̶s̶ energy: Motif Neurotech's Implants for Depression 55:00

11M ago55:00

55:00

Neuromodulation flies in the face of modern psychiatry. It can significantly improve mental health without drugs. It allows us to stimulate or inhibit activity in precise regions of the brain using electricity, magnetism or ultrasound. Motif Neurotech is pioneering minimally invasive implants to precisely deliver neuromodulation for mental health. …

1
Holy poop! Mental health and the gut (part 2 with Bloom Science) 40:15

12M ago40:15

40:15

In part 2 of a 2-part series, Greg and Matias explore microbial therapeutics for mental health with Dr. Christopher Reyes, biophysist, serial enterepreneur, and founder of Bloom Science. Dr. Reyes' research on leveraging microbes to treat neurological conditions began at UC San Francisco. He is now translating his microbiome research into startups …

1
Holy poop! Mental health and the gut (part 1 with Holobiome) 48:48

1y ago48:48

48:48

Business Trip launched in 2020 as a podcast focused on psychedelics. As Matias and Greg started to dive deeper into the complexities of mental health, they met more and more entrepreneurs and scientists creating novel treatments across many areas of mental health, including the gut microbiome. Dr. Phil Strandwitz pulls back the curtain on the gut-b…

1
Ketamine for OCD: Carolyn Rodriguez (Stanford pt 3) 38:28

1y ago38:28

38:28

Stanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body. This is part 3 of a 3-part series, where we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We conclude the…

1
Are psychedelics effective under anesthesia?: Boris Heifets (Stanford pt 2) 37:28

1y ago37:28

37:28

Stanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body. This is part 2 of a 3-part series, where we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We continue wit…

1
The Startup Landscape for Expanding Consciousness 1:21:12

1y ago1:21:12

1:21:12

Psychedelics have long been known to induce altered states of consciousness. But there are many other techniques that can also expand our awareness - from meditation and breathwork to exploring dreams, prayer, light and sound. In this episode, Greg speaks with Scott Britton about the emerging startup landscape around tools for expanding consciousne…

1
Stanford Psychedelic Overview: Robert Malenka (Stanford pt 1) 51:18

1y ago51:18

51:18

Stanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body. In this 3-part series, we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We start the series with Robert M…

1
Live from Psychedelic Science 2023 56:44

1y ago56:44

56:44

Psychedelic Science 2023, Learning Man, MAPS Burn...whatever you want to call it...was a magical conference organized by MAPS. 12k people made the pilgrimage to Denver to discuss psychedelic science, culture, business, art, spirituality, and more. Rick Doblin called this the "Psychedelic 20's" and this event felt like a watershed moment. Luckily, G…

1
What VCs Look for in Psychedelic Companies 41:57

1+ y ago41:57

41:57

What does it take for a traditional VC to fund a psychedelic company? In our latest episode, Matias takes us behind the scenes of a panel discussion at the Psychedelic Therapeutics & Drug Development Conference in San Francisco, CA. Matias talks with VCs at firms with $100M+ fund sizes: Anne Dwane, a partner at Village Global, Amanda Way, principal…

1
Developing Non-Hallucinogenic Psychedelics: Bryan Roth 49:55

1+ y ago49:55

49:55

In our latest episode, Greg and Matias engage in an insightful discussion with Dr. Bryan Roth, the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina Chapel Hill School of Medicine, and the founder of the Roth Lab. Dr. Roth’s lab is on the cutting edge of researching the interaction between brain cell recepto…

1
Behind the Scenes of PsyMed Ventures 35:49

1+ y ago35:49

35:49

In this week's episode, Greg and Matias take a moment to reflect on the opportunities and challenges they have faced while building the PsyMed Ventures syndicate and venture capital fund since starting the Business Trip podcast in 2020. Their ultimate goal is to support founders who are building ethical businesses in frontier mental health technolo…

1
The 2023 Psychedelic Industry Landscape with Psychedelic Alpha 49:51

1+ y ago49:51

49:51

In this week’s episode, Greg and Matias chat with Josh Hardman, the founder of Psychedelic Alpha. Josh is a leading writer and founder at Psychedelic Alpha, an online resource, newsletter, and community covering the intersection of psychedelics and business. He regularly collaborates and writes with experts in the psychedelic field including entrep…

1
The State of Psychedelics (Part 2): Dr. Rachel Yehuda and Zach Haigney (live recording at Soho House) 53:54

1+ y ago53:54

53:54

In this week’s special episode, Matias chats with Dr. Rachel Yehuda and Zach Haigney at Soho House in New York City. This is part 2 of a moderated panel recorded in front of a live audience, with part 1 released in June 2022. Dr. Yehuda has spent the last 30 years doing research on PTSD and trauma and is leading the MDMA-assisted therapy research a…

1
The quest to improve MDMA 55:29

1+ y ago55:29

55:29

This episode shares the story of Tactogen, a drug development company making new chemical entities inspired by MDMA. Co-founder Matt Baggott has been fascinated by MDMA and has studied it for 30 years. And while he believes that MDMA can be effective as a therapeutic, his company is developing an MDMA analogue that is designed to be gentler and saf…

1
Transcranial magnetic stimulation (TMS) paired with ketamine: inside a clinic offering a frontier treatment 50:05

2y ago50:05

50:05

In this new episode of Business Trip, we interview one of the first clinics to offer a protocol that includes TMS (transcranial magnetic stimulation) and ketamine infusion. TMS is a non-invasive procedure that sends electric currents to specific regions in the brain, including areas linked to depression. It's FDA approved and has been gaining adopt…

1
Perspectives from Christian Angermayer, investor and founder in psychedelics 42:34

2y ago42:34

42:34

In this week's episode, we chat with Christian Angermayer. Christian co-founded atai Life Sciences and was an early investor in Compass Pathways -- two of the first companies commercializing psychedelic medicine. Christian also launched a fund dedicated to mental and neurological health called re:Mind, is an investor through his family office Apeir…

1
Soltara: an ethical and profitable ayahuasca retreat 54:34

2y ago54:34

54:34

In this week’s episode, we chat with Melissa Stangl, co-founder of Soltara Healing Center. Soltara is an ayahuasca retreat center whose ceremonies are lead by Shipibo healers, with locations in Peru and Costa Rica. The Shipibo people are from the Peruvian Amazon and are part of a tradition that has been drinking Ayahuasca for healing and spiritual …

1
Microdosing (part 3): The path to FDA approval w/ MindMed and Diamond Therapeutics 58:24

2y ago58:24

58:24

This is final episode in our 3-part series on microdosing that explores the science, history, and clinical applications. In this episode, we discuss the path to FDA approval for microdosing. We chat with the chief medical officers from Diamond Therapeutics and MindMed about their microdosing clinical programs. Diamond's program uses synthetic psilo…

1
Microdosing (part 2): Placebo is a hell of a drug with Balázs Szigeti 37:28

2y ago37:28

37:28

This is part 2 or our 3 part series on microdosing that explore the science, history, and clinical applications. In part 1, we interviewed psychedelic researcher James Fadiman about the fundamentals of microdosing. In part 2, we wanted to understand the placebo effect. In particular, is it the microdose that makes people feel better or it is a plac…

1
Microdosing (part 1): James Fadiman and the fundamentals of microdosing 33:06

2y ago33:06

33:06

In this 3-part series on microdosing, we explore the science, history, and its clinical potential. The anecdotal benefits of microdosing include better mood, creativity, and increased focus. But there are still many unanswered questions that remain. What is an effective dosing protocol? Is it safe in long term use? Does it even work or is it a plac…

1
How the DEA and FDA will regulate psychedelic medicine 48:51

2y ago48:51

48:51

In this week’s episode, we chat with Matt Zorn, an attorney at Yetter Coleman with expertise in DEA law, especially regarding psychedelics. Matt is currently challenging the DEA’s decision to schedule 5 new tryptamines, he recently argued Kathryn Tucker’s psilocybin “Right To Try” case against the DEA, and previously co-led Sue Sisley’s DEA case re…

1
The state of psychedelics: Dr. Rachel Yehuda and Zach Haigney (live recording at Soho House) 45:45

2+ y ago45:45

45:45

In this week’s special episode, Matias chats with Dr. Rachel Yehuda and Zach Haigney at Soho House in New York City. The episode was recorded in front of a live audience. Dr. Yehuda has spent the last 30 years doing research on PTSD and trauma and is leading the MDMA-assisted therapy research at the US Veterans Affairs Medical Center. She is the Di…

1
Empowering the next wave of psychedelic therapists: Journey Clinical 41:41

2+ y ago41:41

41:41

In Episode 18, we chat with Jonathan Sabbagh and Myriam Barthes, the co-founders of Journey Clinical, a platform that enables licensed therapists to offer ketamine-assisted psychotherapy (KAP). Journey Clinical provides licensed therapists with an on-demand KAP-trained medical team, customized treatments for each client, and a portal to connect wit…

1
Osmind and the future of electronic health records in psychedelic medicine 36:19

2+ y ago36:19

36:19

In today’s episode, we chat with Lucia Huang, the CEO and co-founder of Osmind, an electronic health record software system for treatment resistant mental health practices that is already in over 300 clinics. In this episode, we discuss: How Osmind makes data-driven decisions Osmind’s quick growth in only 2 years What it will take for insurance to …

1
Palo Santo on investing in 2nd gen psychedelics and public markets 48:20

2+ y ago48:20

48:20

In today’s episode, we chat with Tim Schlidt, a partner at Palo Santo. Palo Santo is a fund investing in psychedelic therapeutics. Palo Santo’s portfolio includes companies like Eleusis, Tactogen, and Journey Clinical. In this episode, we discuss: Tim’s background in healthcare finance Investing in classic psychedelic compounds vs. 2nd generation c…

1
Designing psychedelic mindstates, with Mindstate Design Labs 56:42

2+ y ago56:42

56:42

Today’s episode features Dillan Dinardo and Tom Ray, the co-founders of Mindstate Design Labs. Mindstate has a unique framework to design psychedelic compounds using what they call the “primer probe method.” This method involves combining a known psychedelic with a non-psychedelic compound. Mindstate just raised an $11.5M seed round. In this episod…

1
MAPS PBC, rethinking the pharma business model and MDMA-assisted therapy 51:44

3y ago51:44

51:44

Today’s episode features Amy Emerson, the CEO of MAPS Public Benefit Corporation (PBC), which is a fully owned subsidiary of MAPS, and its purpose is to commercialize MDMA-assisted therapy. We discuss the MAPS PBC and it’s business model for MDMA-assisted therapy. In this episode, we discuss: MAPS’ protocol and strategy behind FDA clinical trial fo…

1
On transformational ketamine therapy and running an integrative psychedelic clinic 1:03:37

3y ago1:03:37

1:03:37

In today’s episode, we discuss what it’s like being a psychologist who owns a psychedelic clinic. Genesee Herzberg is the co-founder of Sage Integrative Health, an integrative clinic in Berkeley, CA that offers ketamine-assisted therapy (KAP), psychotherapy, somatic therapy, and acupuncture. Genesee discusses her holistic approach to healing, and s…

Podcasts Worth a Listen

Matias Serebrinsky Podcasts

Podcasts Worth a Listen

Quick Reference Guide